v3.25.2
Collaborations, Licensing Arrangements, Other Asset Acquisitions, and Others - Narrative (Details)
$ in Millions
 1 Months Ended
Feb. 28, 2025
USD ($)
Aug. 31, 2023
USD ($)
Apr. 30, 2023
USD ($)
Feb. 28, 2023
USD ($)
payment
Mar. 31, 2025
USD ($)
Jun. 01, 2024
USD ($)
May 01, 2024
USD ($)
Apr. 01, 2024
USD ($)
Mar. 31, 2023
USD ($)
Nimbus Therapeutics, LLC                  
Disclosure of detailed information about intangible assets [line items]                  
Contractual commitments for acquisition of pharmaceutical assets       $ 4,000          
Number of milestone payment, pharmaceutical asset acquisition | payment       2          
Milestone payment, biological asset acquisition agreement       $ 1,000          
First sales milestone, milestone payment, biological assets acquisition agreement       4,000          
Second sales milestone, milestone payment, biological assets acquisition agreement       5,000          
Cash payments for milestone payments   $ 100 $ 900 $ 3,000          
HUTCHMED                  
Disclosure of detailed information about intangible assets [line items]                  
Contractual commitments for acquisition of pharmaceutical assets     $ 400            
Additional potential payment, biological asset acquisition agreement                 $ 730
Protagonist Therapeutics, Inc.                  
Disclosure of detailed information about intangible assets [line items]                  
Contractual commitments for acquisition of pharmaceutical assets               $ 300  
AC Immune SA                  
Disclosure of detailed information about intangible assets [line items]                  
Contractual commitments for acquisition of pharmaceutical assets             $ 100    
Additional potential payment, pharmaceutical asset acquisition agreement             $ 2,100    
Ascentage Pharma                  
Disclosure of detailed information about intangible assets [line items]                  
Contractual commitments for acquisition of pharmaceutical assets           $ 100      
Keros Therapeutic                  
Disclosure of detailed information about intangible assets [line items]                  
Contractual commitments for acquisition of pharmaceutical assets, payment $ 200                
TAK-079 | Blackstone Life Sciences, BXLS | Maximum                  
Disclosure of detailed information about intangible assets [line items]                  
Development funding agreement, receivable         $ 300        
Additional potential payment, regulatory approval milestones         240        
Additional potential payment, cumulative sales milestones         $ 300